Ularitide is a recombinant form of urodilatin, a natriuretic peptide synthesized in the distal tubular cells of the kidney. It regulates renal sodium and water excretion through binding to natriuretic peptide type A receptors, increasing intracellular cyclic guanosine monophosphate (cGMP) levels. While these effects, as well as others such as vasodilation, are also exhibited by other natriuretic peptides, urodilatin has a terminal extension that brings resistance to biological inactivation by neutral endopeptidase, whose activity is increased in decompensated heart failure. Animal studies have demonstrated enhanced diuresis and natriuresis and reduced PCWP (pulmonary capillary wedge pressure) and systemic vascular resistance relative to atrial natriuretic peptide (ANP [99-126], the active circulating isoform). When injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation. Ularitide is currently in Phase 3 development as a potential treatment for patients with acute decompensated heart failure (ADHF).
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28402745
Acute heart failure: continuous intravenous infusion of ularitide at a dose of 15 ng per kilogram of body weight per minute for 48 hours, in addition to accepted therapy.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C307
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Urodilatin
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
SUB11377MIG
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
C056452
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
m11341
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2103920
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
118812-69-4
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
7107
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
C96702
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
740Y5J48Z8
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY | |||
|
DB05034
Created by
admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)